(Q37962692)

26 August 2017

title

Controlled-release interferon alpha 2b, a new member of the interferon family for the treatment of chronic hepatitis C. (English)

1 reference

26 August 2017

Peter L M Jansen

1

1 reference

26 August 2017

Joep De Bruijne

series ordinal

2

1 reference

26 August 2017

language of work or name

English

0 references

publication date

30 November 2011

1 reference

Expert Opinion on Investigational Drugs

26 August 2017

published in

1 reference

26 August 2017

volume

21

1 reference

26 August 2017

issue

1

1 reference

26 August 2017

page(s)

111-118

1 reference

Telaprevir for previously untreated chronic hepatitis C virus infection

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.640671

Boceprevir for untreated chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.640671

Pegylated interferons alpha2a and alpha2b in the treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.640671

Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.640671

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.640671

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.640671

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.640671

Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.640671

Treatment of chronic hepatitis B: Evolution over two decades.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.640671

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.640671

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.640671

Estimating the net contribution of interleukin-28B variation to spontaneous hepatitis C virus clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.640671

Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.640671

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.640671

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.640671

Interferon-lambda serum levels in hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.640671

Insights into the role of interferon lambda in hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.640671

IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.640671

Randomised clinical trial: anti-viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.640671

Safety and antiviral activity of albinterferon alfa-2b in prior interferon nonresponders with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.640671

Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.640671

Novel controlled-release Lemna-derived IFN-alpha2b (Locteron): pharmacokinetics, pharmacodynamics, and tolerability in a phase I clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.640671

Controlled release recombinant human interferon-α2b for treating patients with chronic hepatitis C genotype 1: a phase 2a clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.640671

Polymorphism in xeroderma pigmentosum complementation group C codon 939 and aflatoxin B1-related hepatocellular carcinoma in the Guangxi population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.640671

10.1517/13543784.2012.640671

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference